• K. Höffken


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ahmann FR, Tucson AZ et al. (1986) Zoladex: A monthly depot LH-RH analogue for prostate cancer. Proc Am Soc Clin Oncol 5:412Google Scholar
  2. Bauer HW, Altwein JE (1985) Palliative Therapie des Prostatakarzinoms. Kombination von Androgenentzug und Antiandrogenen. Palliative Therapie des Prostatakarzinoms. Klinische und Experimentelle Urologie, Bd 10. Zuckschwerdt, München Bern WienGoogle Scholar
  3. Chen JJ et al. (1986) Low dose aminoglutethimide treatment of metastatic prostate cancer (Stage D 2) after failure of testicular androgen blockade. Proc Am Soc Clin Oncol 5: 389Google Scholar
  4. de Riese W, Drimalla GH, Sütig T, Aeikens S, Schindler E (1986) Indikation, Komplikationen, Früh-und Spätergebnisse nach radikaler Prostatektomie. Tumor Diagnostik and Therapie 7: 33–36Google Scholar
  5. Eisenberger MA, Simon R et al. (1985) A reevaluation of nonhormonal cytotoxicGoogle Scholar
  6. chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 3:827–837Google Scholar
  7. Fossa SD, Müller A (1976) Treatment of advanced carcinoma of the prostate with estramustine phosphate. J Urol I 15: 406–408Google Scholar
  8. Garnick MB (1985) Long-term efficacy of the GnRH-Analogue, Leuprolide [(Lupron) (LEU)] in metastatic prostate cancer. An Update: Part I. Proc ASCO 4: C-382Google Scholar
  9. Geller J et al. (1983) Comparison of various hormonal therapies for prostatic carcinoma. Semin Oncol 10 [Suppl 4] 4: 34–41Google Scholar
  10. Höffken K (1996) Nichthormonelle Systemtherapie des Prostatakarzinoms. Onkologe 2: 236–240CrossRefGoogle Scholar
  11. Jewett HJ (1975) The present status of radical prostatectomy for stage A and B prostatic cancer. Urol Clin North Am 2: 105–124PubMedGoogle Scholar
  12. Keller J, White JM, Browder H, Lauper D (1986) A phase III randomized trial of megestrol acetate vs diethylstilbestrel in stage D 2 prostate cancer. Preliminary results. Proc Am Soc Clin Oncol 5: 421Google Scholar
  13. Klein LA (1979) Medical progress: Prostatic carcinoma. N Eng J Med 300: 824–833CrossRefGoogle Scholar
  14. Koch P et al. (1992) Continuous infusion 5-fluorouracil (FU) and weekly doxorubicin for hormone resistant prostate cancer. Am Soc Clin Oncol 11: 207Google Scholar
  15. Labrie F, Dupont A, Belanger A (1985) Complete androgen blockade for the treatment of prostate cancer. In: DeVita VT, Hellman S, Rosenberg SA (eds) Important advances in oncology. Lippincott, Philadelphia, pp 193–217Google Scholar
  16. Noldus J, Huland H (1996) Die radikale Prostatektomie beim lokalisierten Prostatakarzinom. Onkologe 2: 224–228CrossRefGoogle Scholar
  17. Paulson DF et al. (1982) Radical surgery versus radiotherapy for adenocarcinoma of the prostate. J Urol 138: 502Google Scholar
  18. Plenta KJ et’al. (1994) Phase-II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol 12: 2005–2012Google Scholar
  19. Prostate Cancer Trialists Collaborative Group (1995) Maximum androgen blockade in advanced prostatic cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 346: 265–269CrossRefGoogle Scholar
  20. Sella A et al. (1994) Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. J Clin Oncol 12: 683–688PubMedGoogle Scholar
  21. Smith JA, Glode LM et al. (1985) Clinical effects of gonadotropin-releasing hormone analogue in metastatic carcinoma of prostate. Urology 25: 106–114PubMedCrossRefGoogle Scholar
  22. Tannock F (1985) Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate? J Clin Oncol 3: 1013–1024PubMedGoogle Scholar
  23. Torti FM et al. (1984) Tamoxifen in advanced prostatic carcinoma. Cancer 54: 739745Google Scholar
  24. Whitmore WF Jr (1963) The rationale and results of ablative surgery for prostatic cancer. Cancer 16: 1119–1132PubMedCrossRefGoogle Scholar
  25. Zimmermann F, Molls M (1996) Strahlentherapie des Prostatakarzinoms. Onkologe 2: 229–234CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1997

Authors and Affiliations

  • K. Höffken

There are no affiliations available

Personalised recommendations